This study aimed to describe real-world VA outcomes in eyes with macular oedema secondary to RVO for up to 60 months after initiation of anti-VEGF therapy, in addition to real-world treatment patterns, and the incidence of pre-defined ocular safety outcomes within 60 months of index anti-VEGF treatment. Here, VEGFA is linked to macular retinal edema.